Grant Funds Development of a Novel Malaria Vaccine - - BioPharm International

ADVERTISEMENT

Grant Funds Development of a Novel Malaria Vaccine



iQur, the UK biotechnology company, and the Edward Jenner Institute for Vaccine Research (University of Oxford) announced that that they will receive a grant of £152,000 ($201,523) from the Technology Strategy Board’s Biocatalyst fund to develop a novel malaria vaccine. The parties to develop a novel virus-like particle (VLP) based vaccine using iQur’s proprietary tandem core technology.

A proof of concept study will be carried out in which iQur will make VLPs carrying specific malaria targets that have been identified by the Jenner. If the project is successful, further funding will be sought to progress the targets into a clinical trial.

Source: iQur

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines

Click here